Brokerages Set Context Therapeutics Inc. (NASDAQ:CNTX) Target Price at $5.25

Key Points

• Context Therapeutics Inc. (NASDAQ:CNTX) has an average rating of "Buy" from analysts, with a target price set at $5.25.
• The company's shares experienced a 6.8% increase, trading at $0.79, while insiders significantly increased their ownership, with the CFO and CEO both purchasing shares.
• Context Therapeutics reported a quarterly earnings loss of ($0.09) EPS, missing expectations of ($0.06) EPS, and analysts forecast a yearly EPS of (-0.51).

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have been assigned an average rating of "Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $5.25.

A number of equities research analysts have recently weighed in on CNTX shares. D. Boral Capital reissued a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, August 7th. Piper Sandler reissued an "overweight" rating and set a $4.00 price objective (down from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. HC Wainwright dropped their price objective on shares of Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, William Blair reaffirmed an "outperform" rating on shares of Context Therapeutics in a report on Tuesday, April 29th.

Context Therapeutics Trading Up 6.8%

Shares of CNTX stock traded up $0.05 during trading hours on Friday, reaching $0.79. 174,696 shares of the company's stock were exchanged, compared to its average volume of 156,103. The stock's 50 day moving average is $0.70 and its 200-day moving average is $0.75. The company has a market cap of $70.53 million, a price-to-earnings ratio of -2.18 and a beta of 1.89. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $2.70.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). Equities analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Insider Activity

In other news, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the stock in a transaction dated Friday, June 6th. The shares were acquired at an average cost of $0.64 per share, with a total value of $25,606.40. Following the purchase, the chief financial officer directly owned 80,010 shares in the company, valued at $51,206.40. The trade was a 100.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martin A. Lehr bought 100,000 shares of the stock in a transaction dated Monday, June 9th. The shares were purchased at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the completion of the purchase, the chief executive officer owned 920,190 shares in the company, valued at approximately $644,133. This represents a 12.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 160,010 shares of company stock worth $107,206. Corporate insiders own 2.80% of the company's stock.

Institutional Trading of Context Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $29,000. Citadel Advisors LLC purchased a new position in Context Therapeutics in the 4th quarter valued at approximately $31,000. Shay Capital LLC purchased a new position in Context Therapeutics in the 4th quarter valued at approximately $52,000. Walleye Capital LLC boosted its position in Context Therapeutics by 51.7% in the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock valued at $175,000 after buying an additional 56,651 shares during the period. Finally, Millennium Management LLC boosted its position in Context Therapeutics by 24.2% in the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after buying an additional 34,835 shares during the period. Institutional investors and hedge funds own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.